Indefinite Delivery Contract SPE2DR25D1961

The Indefinite Delivery Contract (IDC) SPE2DR25D1961 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, is for the provision of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The IDC serves as a primary vehicle for DLA to procure specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The contract has a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion across multiple awards. This unrestricted, fully competitive acquisition aims to establish Prime Vendor Contracts for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), which provides worldwide pharmaceutical support to the Defense Health Agency, DoD customers, the U.S. Coast Guard, and other government agencies. The contract encompasses pharmaceutical products in the 6505 stock catalog/schedule and the current National Drug Code (NDC) database, with separate distribution fees for brand/generic and specialty drugs to support normal and contingency operations globally.

In addition to the DLA contract, AmerisourceBergen also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries through a streamlined, comprehensive contracting mechanism.